Jennifer Venable

Company: The Janssen Pharmaceutical Companies of Johnson & Johnson

Job title: Senior Scientific Director

Seminars:

PANEL DISCUSSION: Exploring the Therapeutic Value of Targeting E3 Ubiquitin Ligases 12:00 pm

Using advanced techniques, our understanding of E3 ligases complex structure has improved, identifying bindable pockets on E3 ubiquitin ligases. Similarly, innovative screening methods have identified ligase binders. With this, how can we begin thinking about these interactions as a starting point for viable Examining the industry standpoint on E3 targeted therapeutics and the overarching strategy…Read more

day: Day Two